SPTLC3: A Potential Drug Target and Biomarker for Cancer and Neurodegenerative Diseases

Target Name: SPTLC3

NCBI ID: G55304

SPTLC3

SPTLC3: A Potential Drug Target and Biomarker for Cancer and Neurodegenerative Diseases

SPTLC3 (Serine Palmitoyl Transferase 3) is a protein that is expressed in various tissues and cells in the body. It is a member of the family of transmembrane proteins known as SPTLCs, which are characterized by the presence of a transmembrane domain and a cytoplasmic tail. SPTLC3 is involved in the transfer of palmitoyl groups between different molecules, including proteins, lipids, and nucleic acids.

SPTLC3 functions as a enzyme that transfer palmitoyl groups from the palmitoyl precursor to the target protein or lipid molecule. This process is critical for the regulation of various cellular processes, including cell signaling, protein synthesis, and lipid metabolism. SPTLC3 is also involved in the regulation of cellular processes that are related to the cell cycle, such as mitosis and meiosis.

SPTLC3 is a protein that has been identified as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. The potential drug targets for SPTLC3 are its role in the regulation of cellular processes that are associated with the disease, as well as its expression levels and its potential interactions with other proteins.

One of the potential drug targets for SPTLC3 is its role in cancer. SPTLC3 has been shown to be involved in the regulation of various cellular processes that are associated with cancer development, including the regulation of cell signaling, angiogenesis, and apoptosis. Studies have shown that high levels of SPTLC3 expression are associated with the development of various types of cancer, including breast, ovarian, and prostate cancer.

Another potential drug target for SPTLC3 is its role in neurodegenerative diseases. SPTLC3 has been shown to be involved in the regulation of various cellular processes that are associated with neurodegenerative diseases, including the regulation of neurotransmitter synthesis and release, and the regulation of protein synthesis. Studies have shown that SPTLC3 is expressed at different levels in the brain and that it is involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

SPTLC3 is also a potential biomarker for various diseases, including cancer and neurodegenerative diseases. The levels of SPTLC3 have been shown to be altered in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. This suggests that SPTLC3 may be a useful biomarker for these diseases, as well as for other cellular processes that are relevant to the disease.

In conclusion, SPTLC3 is a protein that is involved in the transfer of palmitoyl groups between different molecules, including proteins, lipids, and nucleic acids. It is a member of the family of transmembrane proteins known as SPTLCs and is expressed in various tissues and cells in the body. SPTLC3 is involved in the regulation of various cellular processes that are associated with disease development, including cancer, neurodegenerative diseases, and cardiovascular diseases. It is a potential drug target and a potential biomarker for these diseases. Further research is needed to fully understand the role of SPTLC3 in these diseases and to develop effective treatments.

Protein Name: Serine Palmitoyltransferase Long Chain Base Subunit 3

Functions: Serine palmitoyltransferase (SPT). The heterodimer formed with LCB1/SPTLC1 constitutes the catalytic core. The composition of the serine palmitoyltransferase (SPT) complex determines the substrate preference. SPT complexes containing SPTLC3 generate shorter chain sphingoid bases compared to complexes containing SPTLC2. The SPTLC1-SPTLC3-SPTSSA isozyme uses C12-CoA, C14-CoA and C16-CoA as substrates, with a slight preference for C14-CoA. On the other hand, the SPTLC1-SPTLC3-SPTSSB has the ability to use a broader range of acyl-CoAs without apparent preference

The "SPTLC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPTLC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets